Published in J Clin Oncol on September 11, 2006
Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov (2012) 4.30
The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol (2010) 3.57
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol (2013) 2.64
Collagen I promotes epithelial-to-mesenchymal transition in lung cancer cells via transforming growth factor-beta signaling. Am J Respir Cell Mol Biol (2007) 1.78
Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunol Immunother (2008) 1.45
Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer? Breast Cancer Res Treat (2008) 1.41
TGF-β - an excellent servant but a bad master. J Transl Med (2012) 1.41
Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy. Cancer Res (2008) 1.38
Molecular pathways and therapeutic targets in lung cancer. Oncotarget (2014) 1.16
Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea. J Clin Oncol (2013) 1.12
Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas. Oncotarget (2014) 1.08
HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts. J Clin Invest (2012) 1.07
The role of TGF-β in bone metastasis: novel therapeutic perspectives. Bonekey Rep (2012) 1.06
Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer. J Transl Med (2013) 1.06
Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. J Thorac Dis (2013) 1.03
Lung cancer: Biology and treatment options. Biochim Biophys Acta (2015) 1.02
Disruption of TGF-beta signaling prevents the generation of tumor-sensitized regulatory T cells and facilitates therapeutic antitumor immunity. J Immunol (2009) 1.02
Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity. Front Immunol (2014) 1.00
Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res (2013) 0.99
Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res (2016) 0.99
Active-specific immunotherapy for non-small cell lung cancer. J Thorac Dis (2011) 0.99
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol (2015) 0.97
Maintenance and consolidation therapy in patients with unresectable stage III/IV non-small cell lung cancer. Oncologist (2010) 0.96
Whole cell vaccines--past progress and future strategies. Semin Oncol (2012) 0.93
Antigen-specific vaccines for cancer treatment. Hum Vaccin Immunother (2014) 0.89
Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention. Clin Dev Immunol (2012) 0.89
Immunotherapy for lung cancer: advances and prospects. Am J Clin Exp Immunol (2016) 0.89
Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality. Clin Lung Cancer (2010) 0.88
Cancer-associated fibroblasts as targets for immunotherapy. Immunotherapy (2012) 0.88
γδ T-cell immunotherapy for lung cancer. Surg Today (2011) 0.88
Maintenance therapy in advanced non-small cell lung cancer: evolution, tolerability and outcomes. Ther Adv Med Oncol (2011) 0.87
Allogeneic tumor cell vaccines: the promise and limitations in clinical trials. Hum Vaccin Immunother (2013) 0.87
Lung cancer vaccines: current status and future prospects. Transl Lung Cancer Res (2014) 0.86
Immunotherapy prospects in the treatment of lung cancer and mesothelioma. Transl Lung Cancer Res (2014) 0.85
Gene therapy for lung neoplasms. Clin Chest Med (2011) 0.84
Immunotherapy for non-small cell lung cancer. Tuberc Respir Dis (Seoul) (2014) 0.82
Selected anti-tumor vaccines merit a place in multimodal tumor therapies. Front Oncol (2012) 0.82
Why has active immunotherapy not worked in lung cancer? Ann Oncol (2015) 0.82
Biomarkers of safety and immune protection for genetically modified live attenuated leishmania vaccines against visceral leishmaniasis - discovery and implications. Front Immunol (2014) 0.82
Locally advanced lung cancer: an optimal setting for vaccines and other immunotherapies. Cancer J (2013) 0.82
Lung cancer vaccines. Cancer J (2011) 0.82
Immunotherapy in lung cancer. Transl Lung Cancer Res (2014) 0.82
What lies within: novel strategies in immunotherapy for non-small cell lung cancer. Oncologist (2013) 0.81
Differential knockdown of TGF-β ligands in a three-dimensional co-culture tumor- stromal interaction model of lung cancer. BMC Cancer (2014) 0.81
Actual status of therapeutic vaccination in non-small cell lung cancer. Contemp Oncol (Pozn) (2014) 0.80
Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer. Cancer Med (2016) 0.80
The efficacy and safety of immunotherapy in patients with advanced NSCLC: a systematic review and meta-analysis. Sci Rep (2016) 0.79
Chemotherapeutic Targeting of the Transforming Growth Factor-β Pathway in Breast Cancers. Breast Cancer Manag (2015) 0.79
Cancer stem cells and immunoresistance: clinical implications and solutions. Transl Lung Cancer Res (2015) 0.79
Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer. Dis Markers (2016) 0.78
Re-examination of maintenance therapy in non-small cell lung cancer with the advent of new anti-cancer agents. Drugs (2013) 0.78
Trends and advances in tumor immunology and lung cancer immunotherapy. J Exp Clin Cancer Res (2016) 0.78
Therapeutic cancer vaccines: the latest advancement in targeted therapy. Am J Ther (2012) 0.78
Immunotherapy of malignant gliomas using autologous and allogeneic tissue cells. Anticancer Agents Med Chem (2010) 0.78
Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting. Ann Transl Med (2016) 0.77
Tgf-Beta superfamily receptors-targets for antiangiogenic therapy? J Oncol (2010) 0.77
Prioritization schema for immunotherapy clinical trials in glioblastoma. Oncoimmunology (2016) 0.76
Recent advances in immunotherapy for non-small-cell lung cancer. Hum Vaccin Immunother (2013) 0.76
Adaptation of ovarian cancer cells to the peritoneal environment: Multiple mechanisms of the developmental patterning gene HOXA9. Cancer Cell Microenviron (2014) 0.76
Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol (2014) 0.75
Therapeutic vaccines in non-small cell lung cancer. Immunotargets Ther (2013) 0.75
TGF-β Signaling in Gastrointestinal Cancers: Progress in Basic and Clinical Research. J Clin Med (2017) 0.75
Respiratory Homeostasis and Exploitation of the Immune System for Lung Cancer Vaccines. US Oncol (2009) 0.75
NSCLC - immunogenic after all? J Thorac Dis (2011) 0.75
Developing a vaccine for non-small-cell lung cancer. Commentary. Postgrad Med (2009) 0.75
Revisiting of cancer vaccine?-Specific immunotherapy comes to field with the biomarker. Ann Transl Med (2016) 0.75
Cancer targeting vaccines: surrogate measures of activity. Hum Vaccin Immunother (2013) 0.75
Current state of immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res (2017) 0.75
Transforming Growth Factor-beta: A Therapeutic Target for Cancer. Hum Vaccin Immunother (2017) 0.75
The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology (2006) 2.63
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol (2004) 2.09
siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev (2009) 1.91
Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J Clin Oncol (2005) 1.83
Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study. Mol Ther (2005) 1.81
New-onset postoperative atrial fibrillation and long-term survival after aortic valve replacement surgery. Ann Thorac Surg (2010) 1.55
Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther (2005) 1.53
New-onset postoperative atrial fibrillation after isolated coronary artery bypass graft surgery and long-term survival. Circ Cardiovasc Qual Outcomes (2009) 1.53
Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. Cancer Invest (2004) 1.51
Stathmin 1: a novel therapeutic target for anticancer activity. Expert Rev Anticancer Ther (2008) 1.51
A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Ther (2009) 1.50
mda-7/IL-24: exploiting cancer's Achilles' heel. Mol Ther (2005) 1.46
Established preoperative risk factors do not predict long-term survival in isolated coronary artery bypass grafting patients. Ann Thorac Surg (2012) 1.44
Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther (2003) 1.40
Immediate open repair vs surveillance in patients with small abdominal aortic aneurysms: survival differences by aneurysm size. Mayo Clin Proc (2013) 1.39
Monoclonal antibodies in cancer therapy: 25 years of progress. J Clin Oncol (2008) 1.38
Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Cancer (2012) 1.36
mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review). Int J Oncol (2007) 1.34
A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin Cancer Res (2011) 1.27
Bilateral alteration in stepping pattern after unilateral motor cortex injury: a new test strategy for analysis of skilled limb movements in neurological mouse models. J Neurosci Methods (2005) 1.26
Categorizing BMI may lead to biased results in studies investigating in-hospital mortality after isolated CABG. J Clin Epidemiol (2007) 1.26
EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study. Gastrointest Endosc (2012) 1.19
Oncolytic viruses for induction of anti-tumor immunity. Curr Pharm Biotechnol (2012) 1.18
Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer. Mol Ther (2011) 1.15
Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma. Toxicol Appl Pharmacol (2006) 1.12
RNA interference and cancer therapy. Pharm Res (2011) 1.11
TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and long-term follow-up. Ann Surg Oncol (2005) 1.02
CAP37, a neutrophil-derived inflammatory mediator, augments leukocyte adhesion to endothelial monolayers. Microvasc Res (2003) 1.01
Activation of FFA1 mediates GLP-1 secretion in mice. Evidence for allosterism at FFA1. Mol Cell Endocrinol (2013) 1.00
A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities. Clin Cancer Res (2004) 1.00
Phase I trial of TGF-beta 2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine. Clin Cancer Res (2011) 0.99
Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol (2008) 0.97
Fasting glucose levels in predicting 1-year all-cause mortality in patients who do not have diabetes and are on maintenance hemodialysis. J Am Soc Nephrol (2007) 0.94
Corneal expression of the inflammatory mediator CAP37. Invest Ophthalmol Vis Sci (2002) 0.94
Hereditary inclusion body myopathy: single patient response to intravenous dosing of GNE gene lipoplex. Hum Gene Ther (2011) 0.93
Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Ther (2003) 0.93
Establishment of stable cell lines for personalized melanoma cell vaccine. Melanoma Res (2010) 0.93
Immunoglobulin M myeloma: evaluation of molecular features and cytokine expression. Clin Lymphoma (2005) 0.90
Phase I trial of PT-100 (PT-100), a cytokine-inducing small molecule, following chemotherapy for solid tumor malignancy. Cancer Invest (2006) 0.90
A hospital-randomized controlled trial of an educational quality improvement intervention in rural and small community hospitals in Texas following implementation of information technology. Am J Med Qual (2007) 0.90
Hereditary inclusion body myopathy: single patient response to GNE gene Lipoplex therapy. J Gene Med (2010) 0.90
CAP37, a novel inflammatory mediator: its expression in endothelial cells and localization to atherosclerotic lesions. Am J Pathol (2002) 0.89
PDX-1 is a therapeutic target for pancreatic cancer, insulinoma and islet neoplasia using a novel RNA interference platform. PLoS One (2012) 0.88
Web-based three-dimensional Virtual Body Structures: W3D-VBS. J Am Med Inform Assoc (2002) 0.88
Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer. Mol Ther (2006) 0.88
Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors. Cancer Invest (2005) 0.87
Activation of microglia: a neuroinflammatory role for CAP37. Glia (2003) 0.87
Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer. Gastrointest Endosc (2012) 0.87
Phase 2 trial of Allovectin-7 in advanced metastatic melanoma. Melanoma Res (2006) 0.87
Obesity and stroke after cardiac surgery: the impact of grouping body mass index. Ann Thorac Surg (2007) 0.86
Summary of bi-shRNA/GM-CSF augmented autologous tumor cell immunotherapy (FANG™) in advanced cancer of the liver. Oncology (2014) 0.86
Functional modulation of smooth muscle cells by the inflammatory mediator CAP37. Microvasc Res (2004) 0.86
Relation of obesity to atrial fibrillation after isolated coronary artery bypass grafting. Am J Cardiol (2008) 0.86
Monitoring response to treatment in melanoma patients: potential of a serum glycomic marker. Int J Cancer (2008) 0.85
In vivo safety and antitumor efficacy of bifunctional small hairpin RNAs specific for the human Stathmin 1 oncoprotein. DNA Cell Biol (2011) 0.85
Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia. Mol Cancer Ther (2014) 0.85
Pivotal role of CD38 biomarker in combination with CD24, EpCAM, and ALDH for identification of H460 derived lung cancer stem cells. J Stem Cells (2011) 0.84
RNA interference and personalized cancer therapy. Discov Med (2013) 0.83
Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of cancer biotherapy research group 94-10. Cancer Biother Radiopharm (2002) 0.83
Effect of body mass index on risk of long-term mortality following coronary artery bypass grafting. Am J Cardiol (2006) 0.83
Comparing long-term survival between patients undergoing off-pump and on-pump coronary artery bypass graft operations. Ann Thorac Surg (2011) 0.83
Hereditary Inclusion Body Myopathy (HIBM2). Gene Regul Syst Bio (2009) 0.82
Radioimmunotherapy for non-Hodgkin's lymphoma with yttrium 90 ibritumomab tiuxetan. Clin J Oncol Nurs (2002) 0.82
Developing an effective lung cancer program in a community hospital setting. Clin Lung Cancer (2009) 0.81
Fine genetic mapping of RXopJ4, a bacterial spot disease resistance locus from Solanum pennellii LA716. Theor Appl Genet (2012) 0.80
Lack of elevation of serum S100B in patients with metastatic melanoma as a predictor of outcome after induction with an autologous vaccine of proliferating tumor cells and dendritic cells. Cancer Biother Radiopharm (2008) 0.80
Emerging new therapies for chemotherapy-resistant cancer using adenoviral vectors. Drug Resist Updat (2002) 0.80
Molecular integrity and global gene expression of breast and lung cancer stem cells under long-term storage and recovery. Cell Tissue Bank (2012) 0.80
Modeling the effects of body mass index and waist-to-hip ratio on mortality. Eur J Epidemiol (2007) 0.80
The stability of breast cancer progenitor cells during cryopreservation: Maintenance of proliferation, self-renewal, and senescence characteristics. Cryobiology (2010) 0.80
CD24+/CD38- as new prognostic marker for non-small cell lung cancer. Multidiscip Respir Med (2013) 0.79
Preclinical assessment of wt GNE gene plasmid for management of hereditary inclusion body myopathy 2 (HIBM2). Gene Regul Syst Bio (2008) 0.79